Q1 Earnings Forecast for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Celcuity in a research note issued on Monday, April 28th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.94) per share for the quarter. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. Leerink Partnrs also issued estimates for Celcuity's Q2 2025 earnings at ($1.06) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($4.25) EPS, FY2026 earnings at ($3.58) EPS and FY2027 earnings at $0.28 EPS.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13).

CELC has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price target on shares of Celcuity in a research report on Friday, April 11th. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Celcuity in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $30.17.

Celcuity Trading Up 0.9 %

Shares of NASDAQ:CELC traded up $0.10 during trading on Thursday, reaching $10.90. The stock had a trading volume of 208,420 shares, compared to its average volume of 299,069. Celcuity has a 52 week low of $7.58 and a 52 week high of $19.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm's fifty day moving average is $10.03 and its 200 day moving average is $12.04. The stock has a market cap of $412.45 million, a price-to-earnings ratio of -4.18 and a beta of 0.56.

Institutional Investors Weigh In On Celcuity

Several hedge funds and other institutional investors have recently modified their holdings of CELC. Geode Capital Management LLC grew its position in Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company's stock valued at $9,401,000 after purchasing an additional 136,518 shares during the period. Barclays PLC lifted its position in Celcuity by 567.6% in the 3rd quarter. Barclays PLC now owns 53,605 shares of the company's stock valued at $800,000 after acquiring an additional 45,576 shares in the last quarter. Bleakley Financial Group LLC bought a new position in Celcuity in the 4th quarter valued at about $146,000. Corebridge Financial Inc. boosted its stake in Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company's stock valued at $213,000 after purchasing an additional 1,858 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Celcuity by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock worth $21,624,000 after purchasing an additional 24,429 shares during the last quarter. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.